Stock News

Bnp Paribas Investment Partners Sa Boosted Boston Beer (SAM) Position By $899,419; 1 Analysts Covering Vascular Biogenics Ltd. (VBLT)

Vascular Biogenics Ltd. (NASDAQ:VBLT) Logo

Among 5 analysts covering Vascular Biogenics (NASDAQ:VBLT), 1 have Buy rating, 0 Sell and 4 Hold. Therefore 20% are positive. Vascular Biogenics had 18 analyst reports since August 24, 2015 according to SRatingsIntel. Chardan Capital Markets initiated the stock with “Buy” rating in Monday, September 21 report. The rating was downgraded by Chardan Capital Markets to “Neutral” on Friday, March 9. The firm has “Neutral” rating given on Thursday, March 8 by H.C. Wainwright. The stock of Vascular Biogenics Ltd. (NASDAQ:VBLT) has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The company was maintained on Thursday, March 22 by H.C. Wainwright. The stock of Vascular Biogenics Ltd. (NASDAQ:VBLT) has “Hold” rating given on Thursday, March 8 by JMP Securities. The rating was upgraded by JMP Securities on Monday, September 21 to “Mkt Outperform”. The stock of Vascular Biogenics Ltd. (NASDAQ:VBLT) has “Hold” rating given on Thursday, March 8 by Piper Jaffray. The company was maintained on Tuesday, October 3 by H.C. Wainwright. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, March 28. See Vascular Biogenics Ltd. (NASDAQ:VBLT) latest ratings:

22/03/2018 Broker: H.C. Wainwright Rating: Hold New Target: $3.0 Maintain
09/03/2018 Broker: Chardan Capital Markets Old Rating: Buy New Rating: Neutral Downgrade
08/03/2018 Broker: JMP Securities Rating: Hold Downgrade
08/03/2018 Broker: Piper Jaffray Rating: Hold Downgrade
08/03/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Neutral Old Target: $11 Downgrade

Bnp Paribas Investment Partners Sa increased Boston Beer Inc (SAM) stake by 17.78% reported in 2017Q4 SEC filing. Bnp Paribas Investment Partners Sa acquired 4,709 shares as Boston Beer Inc (SAM)’s stock declined 2.25%. The Bnp Paribas Investment Partners Sa holds 31,190 shares with $5.96 million value, up from 26,481 last quarter. Boston Beer Inc now has $2.68B valuation. The stock increased 0.77% or $1.75 during the last trading session, reaching $227.85. About 4,549 shares traded. The Boston Beer Company, Inc. (NYSE:SAM) has risen 25.34% since May 8, 2017 and is uptrending. It has outperformed by 13.79% the S&P500.

It closed at $2.2 lastly. It is down 59.29% since May 8, 2017 and is downtrending. It has underperformed by 70.84% the S&P500.

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company has market cap of $65.77 million. The companyÂ’s program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. It currently has negative earnings. The Company’s lead product candidate is VB-111, a gene biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and has completed Phase II clinical trials for recurrent platinum-resistant ovarian cancer, as well as for iodine-resistant differentiated thyroid cancer.

More notable recent Vascular Biogenics Ltd. (NASDAQ:VBLT) news were published by: Nasdaq.com which released: “VBL Therapeutics to Present Data on its MOSPD2 Oncology Program at MIXiii-BIOMED 2018 on May 15” on May 07, 2018, also Globenewswire.com with their article: “VBL Therapeutics to Report First Quarter 2018 Financial Results on May 17” published on May 01, 2018, Globenewswire.com published: “VBL Therapeutics Awarded $2.5 Million Non-Dilutive Grant by the Israel Innovation Authority” on April 09, 2018. More interesting news about Vascular Biogenics Ltd. (NASDAQ:VBLT) were released by: Streetinsider.com and their article: “VBL Therapeutics (VBLT) Presents Late Breaking Research Demonstrating Immune-cell Mediated Killing of Cancer …” published on April 16, 2018 as well as Globenewswire.com‘s news article titled: “VBL Therapeutics to Present Late-Breaking Research at the American Association for Cancer Research (AACR) 2018 …” with publication date: April 10, 2018.

Bnp Paribas Investment Partners Sa decreased Qts Rlty Tr Inc (NYSE:QTS) stake by 50,189 shares to 349,586 valued at $18.93M in 2017Q4. It also reduced Allegion Pub Ltd Co (NYSE:ALLE) stake by 24,255 shares and now owns 48,123 shares. Bank Of The Ozarks (NASDAQ:OZRK) was reduced too.

Since December 13, 2017, it had 0 insider buys, and 23 insider sales for $30.06 million activity. ROPER MARTIN F sold $147,351 worth of stock or 773 shares. Another trade for 8,117 shares valued at $1.53M was made by Geist John C on Tuesday, January 2. HEATH TARA L. sold 64 shares worth $12,090. Burwick David A had sold 5,000 shares worth $950,050. Another trade for 1,000 shares valued at $225,000 was sold by Grinnell David L.. Fisher Cheryl also sold $17,569 worth of The Boston Beer Company, Inc. (NYSE:SAM) on Tuesday, January 2.

Investors sentiment decreased to 0.87 in 2017 Q4. Its down 0.28, from 1.15 in 2017Q3. It dived, as 25 investors sold SAM shares while 90 reduced holdings. 44 funds opened positions while 56 raised stakes. 8.44 million shares or 3.57% less from 8.75 million shares in 2017Q3 were reported. Citadel Advsr Ltd invested 0% of its portfolio in The Boston Beer Company, Inc. (NYSE:SAM). Driehaus Capital Limited Liability Corporation, Illinois-based fund reported 4,555 shares. Weaver C Barksdale Associate Inc reported 25 shares stake. Endurance Wealth Management holds 0.02% or 700 shares. Teacher Retirement Sys Of Texas accumulated 0% or 3,074 shares. Citigroup, New York-based fund reported 2,892 shares. Shaker Investments Llc Oh reported 0.17% in The Boston Beer Company, Inc. (NYSE:SAM). Hudson Bay Ltd Partnership reported 0.03% in The Boston Beer Company, Inc. (NYSE:SAM). Architects Incorporated holds 2 shares or 0% of its portfolio. Panagora Asset Mngmt holds 0.07% of its portfolio in The Boston Beer Company, Inc. (NYSE:SAM) for 100,962 shares. Millennium Management Ltd Liability holds 11,322 shares or 0% of its portfolio. Sei Investments Company has 0% invested in The Boston Beer Company, Inc. (NYSE:SAM). Gemmer Asset Lc has invested 0% in The Boston Beer Company, Inc. (NYSE:SAM). Smith Graham Ltd Partnership holds 0.99% in The Boston Beer Company, Inc. (NYSE:SAM) or 55,208 shares. The Michigan-based Usa Financial Portformulas has invested 0.11% in The Boston Beer Company, Inc. (NYSE:SAM).

The Boston Beer Company, Inc. (NYSE:SAM) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *